Literature DB >> 24149187

New victims of current drug laws.

David J Nutt1, Leslie A King, David E Nichols.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24149187     DOI： 10.1038/nrn3530-c2

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN： 1471-003X            Impact factor:   34.870


× No keyword cloud information.
  3 in total

1.  Controlled substances and innovation of biomedicine: a preclinical perspective.

Authors:  Adam Michael Stewart; Allan V Kalueff
Journal:  Nat Rev Neurosci       Date:  2013-10-23       Impact factor: 34.870

2.  Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36.

Authors:  Anders Ettrup; Søren Holm; Martin Hansen; Muhammad Wasim; Martin Andreas Santini; Mikael Palner; Jacob Madsen; Claus Svarer; Jesper Langgaard Kristensen; Gitte Moos Knudsen
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

3.  Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Authors:  David J Nutt; Leslie A King; David E Nichols
Journal:  Nat Rev Neurosci       Date:  2013-06-12       Impact factor: 34.870
  3 in total
  3 in total

1.  Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science".

Authors:  David Nutt
Journal:  EMBO Rep       Date:  2014-02-14       Impact factor: 8.807

2.  Illegal drugs laws: clearing a 50-year-old obstacle to research.

Authors:  David Nutt
Journal:  PLoS Biol       Date:  2015-01-27       Impact factor: 8.029

3.  How Drug Control Policy and Practice Undermine Access to Controlled Medicines.

Authors:  Naomi Burke-Shyne; Joanne Csete; Duncan Wilson; Edward Fox; Daniel Wolfe; Jennifer J K Rasanathan
Journal:  Health Hum Rights       Date:  2017-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.